速递｜预计礼来替尔泊肽的全球销售额将达620亿美金，成为2030年全球药王

GLP1减重宝典2025-07-14

整理 | GLP1减重宝典内容团队根据Evaluate Pharma的数据，受益于糖尿病和肥胖治疗药物销售的持续增长，礼来（Eli Lilly）有望在2030年成为全球处方药销售额最高的生物制药公司，预计届时销售收入将达到1130亿美元，远超排名第二的诺和诺德（Novo Nordisk），后者预计为840亿美元。在其发布的《2025年全球前瞻》报告中，Evaluate指出，糖尿病与肥胖药物将继续...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2551973277?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-14 11:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2551973277","market":"us","top_or_hot":-1,"title":"速递｜预计礼来替尔泊肽的全球销售额将达620亿美金，成为2030年全球药王","media":"GLP1减重宝典","content":"<div>\n<p>整理 | GLP1减重宝典内容团队根据Evaluate Pharma的数据，受益于糖尿病和肥胖治疗药物销售的持续增长，礼来（Eli Lilly）有望在2030年成为全球处方药销售额最高的生物制药公司，预计届时销售收入将达到1130亿美元，远超排名第二的诺和诺德（Novo Nordisk），后者预计为840亿美元。在其发布的《2025年全球前瞻》报告中，Evaluate指出，糖尿病与肥胖药物将继续...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714111012a448d353&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>速递｜预计礼来替尔泊肽的全球销售额将达620亿美金，成为2030年全球药王</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n速递｜预计礼来替尔泊肽的全球销售额将达620亿美金，成为2030年全球药王\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-14 11:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714111012a448d353&s=b><strong>GLP1减重宝典</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>整理 | GLP1减重宝典内容团队根据Evaluate Pharma的数据，受益于糖尿病和肥胖治疗药物销售的持续增长，礼来（Eli Lilly）有望在2030年成为全球处方药销售额最高的生物制药公司，预计届时销售收入将达到1130亿美元，远超排名第二的诺和诺德（Novo Nordisk），后者预计为840亿美元。在其发布的《2025年全球前瞻》报告中，Evaluate指出，糖尿病与肥胖药物将继续...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714111012a448d353&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2265009873.SGD","symbol_name":"Eastspring Investments - Global Growth Equity AS SGD-H","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714111012a448d353&s=b","article_id":"2551973277","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714111012a448d353&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2551973277","pubTimestamp":1752462045,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"其中，礼来的糖尿病治疗药物替尔泊肽预计将在2030年成为全球最畅销药物，销售额高达360亿美元，而其用于减重的Zepbound则将位列第三，销售额为255亿美元。Evaluate预计，礼来和诺和诺德将在2030年前迅速超越上述公司。相比之下，诺华与辉瑞的销售额在2024至2030年期间则可能出现轻微下滑。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU0882574055.USD":"富达全球健康医疗A ACC","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","BK4007":"制药","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU2746668461.USD":"MANULIFE DYNAMIC LEADERS \"AA\" (USD) ACC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","LU2063271972.USD":"富兰克林创新领域基金","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","BK4534":"瑞士信贷持仓","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","BK4585":"ETF&股票定投概念","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU1232071149.USD":"AZ FUND 1 GLOBAL GROWTH SELECTOR \"AAZ\" (USDHDG) ACC","LU0203201768.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LLY":"礼来","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","BK4516":"特朗普概念","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","LU0079474960.USD":"联博美国增长基金A","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","LU1127390331.HKD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A\" (HKD) ACC","SG9999014906.USD":"大华全球优质成长基金Acc USD","LU0882574139.USD":"富达环球消费行业基金A ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC"},"translate_title":"Express | It is estimated that Eli Lilly's global sales of telpotide will reach 62 billion US dollars, becoming the global drug king in 2030","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1},"content_text":"整理 | GLP1减重宝典内容团队根据Evaluate Pharma的数据，受益于糖尿病和肥胖治疗药物销售的持续增长，礼来（Eli Lilly）有望在2030年成为全球处方药销售额最高的生物制药公司，预计届时销售收入将达到1130亿美元，远超排名第二的诺和诺德（Novo Nordisk），后者预计为840亿美元。在其发布的《2025年全球前瞻》报告中，Evaluate指出，糖尿病与肥胖药物将继续主导市场，预计2024年至2030年间年均增长率将达到20%。其中，礼来将从这一增长中获益更多，其2024年处方药销售额为410亿美元，而诺和诺德则为420亿美元，预计至2030年二者均将实现大幅增长。到2030年，GLP-1受体激动剂及相关药物组合将占全球处方药市场近9%的份额。Evaluate指出，这类药物“已经成为一个独立的重要品类”，预计将达到前所未有的销售高峰。其中，礼来的糖尿病治疗药物替尔泊肽（Mounjaro）预计将在2030年成为全球最畅销药物，销售额高达360亿美元，而其用于减重的Zepbound则将位列第三，销售额为255亿美元。与此同时，诺和诺德的三款GLP-1药物也将跻身2030年全球处方药销售前十：分别是用于糖尿病治疗的司美格鲁肽（Ozempic，244亿美元），减重药物Wegovy（181亿美元），以及尚未获批的下一代肥胖治疗药物Cagrisema（152亿美元）。Evaluate还预测，到2030年将有三款临床阶段的肥胖药物进入全球销售前十榜单。其中两款来自礼来：口服GLP-1药物Orforglipron（预计销售127亿美元）以及三重机制药物Retatrutide（56亿美元）；另一款来自安进（Amgen），名为MariTide，预计将实现销售37亿美元。从目前来看，2024年全球处方药销售额排名前七的公司分别为：强生（Johnson & Johnson，557亿美元）、艾伯维（AbbVie，545亿美元）、默沙东（Merck，543亿美元）、罗氏（Roche，525亿美元）、辉瑞（Pfizer，520亿美元）、阿斯利康（AstraZeneca，509亿美元）以及诺华（Novartis，502亿美元）。Evaluate预计，礼来和诺和诺德将在2030年前迅速超越上述公司。在这些公司中，艾伯维的增长最为显著，预计到2030年其处方药销售将增至753亿美元，主要得益于其免疫炎症类药物Skyrizi（预计266亿美元）与Rinvoq（预计148亿美元）。强生则有望将其处方药销售额提升至678亿美元，其中抗肿瘤药Darzalex将在2030年实现166亿美元销售额。赛诺菲（Sanofi）预计将从2024年的442亿美元增长至648亿美元，其中与再生元（Regeneron）联合开发的重磅药Dupixent在2030年预计将实现250亿美元的销售额。阿斯利康的增长也十分可观，预计2030年将达到644亿美元，部分增长归因于其与第一三共（Daiichi Sankyo）联合开发的抗体偶联药物Enhertu（预计销售额152亿美元）。尽管罗氏在2030年销售榜单上并无单款药物进入前十，但其整体处方药销售预计将从525亿美元增长至663亿美元。默沙东的处方药销售则预计从去年的543亿美元增长至600亿美元。尽管其明星产品Keytruda（可瑞达）预计将在2028年遭遇生物类似药冲击，2030年销售下滑至170亿美元，但公司通过开发皮下注射剂型的Keytruda进行产品生命周期管理，这一新剂型预计将在2030年实现76亿美元销售额，Evaluate称其为“生命周期管理的典范”。相比之下，诺华与辉瑞的销售额在2024至2030年期间则可能出现轻微下滑。从Evaluate的整体分析来看，糖尿病与肥胖治疗市场的迅猛扩张正深刻重塑全球制药行业格局，尤其是GLP-1类药物，其变革性作用正推动礼来与诺和诺德成为行业新王者。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2551973277","isCrawlerRequest":true}